Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study

Date 26 September 2015
Event European Cancer Congress 2015
Session Head and Neck Cancer
Topics Head and Neck Cancers
Presenter Hsu, C.